The ≥5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer - Archive ouverte HAL
Communication Dans Un Congrès Année : 2018

The ≥5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer

Domaines

Cancer

Mouniati COLO  : Connectez-vous pour contacter le contributeur

https://hal.science/hal-01936152

Soumis le : mardi 27 novembre 2018-11:48:55

Dernière modification le : vendredi 22 décembre 2023-10:29:46

Fichier non déposé

Dates et versions

hal-01936152 , version 1 (27-11-2018)

Identifiants

  • HAL Id : hal-01936152 , version 1

Citer

Wilfrid Finck, Judith Passildas, Camille Poirier, Fabrice Kwiatkowski, Catherine Abrial, et al.. The ≥5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer. Breast Cancer Symposium, Dec 2018, SAN ANTONIO, United States. ⟨hal-01936152⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-LILLE3 PRES_CLERMONT IMOST
57 Consultations
0 Téléchargements

Partager

More